Slide 1: Q3 2022 Earnings and Business Update Call
Q3 2022 Earnings and Business Update Call «: Sanara ~ MedTech Evidence Based Healing ee e e #e« @¢
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Commentary on Q3 2022
Commentary on Q3 2022 . Financial Update + Highest sales quarter ($13.0 million total including Scendia sales of $3.0 million) in the Company’s history for the business, as well as, for the historical business before the Scendia acquisition; first quarter in which the Company generated >$4 million i
Slide 4: Surgical Products
Surgical Products Surgical Overview 36 field sales managers CellerateRX® Surgical sold in 662“) hospitals/ASCs in the TTM CellerateRX® Surgical sold in hospitals/ASCs across 28 states) in the TTM CellerateRX® Surgical approved to be sold in 1,593 hospitals/ASCs Total estimated available market in th
Slide 5: Scendia Biologics Acquisition
Scendia Biologics Acquisition Overview * Continued integration of Scendia into Sanara during the third quarter + In Q3, Scendia generated $3.0 million in revenue for Sanara + Primary Scendia Products: + AMPLIFY™ Verified Inductive Bone Matrix + ALLOCYTE™ Advanced Cellular Bone Matrix + BiFORM® Bioac
Slide 6: InfuSystem Partnership Overview
Overview * The partnership is focused on delivering a complete wound care solution targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction + The partnership is expected to enable InfuSystem to offer innovative products including Cork Medica
Slide 7: Q3 2022 Financial Highlights
Q3 2022 Financial Highlights Overview + Revenue + For the quarter, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period. * Third quarter revenues included $3.
Slide 8: Questions
Questions . Sanara MedTech Evidence Based Healing